HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Oncology3 papers

Desmoplastic malignant melanoma

Last edited: 4/15/2026

Overview

Desmoplastic malignant melanoma is a rare variant characterized by dense fibrous stroma surrounding neoplastic melanocytes, often presenting with advanced disease and challenging treatment options 1.

Diagnosis

  • Clinical presentation includes firm, deeply seated nodules with rapid growth 1.
  • Histopathology confirms dense collagenous stroma with atypical melanocytes 1.
  • Immunohistochemistry may aid in distinguishing from other spindle cell neoplasms 1.
  • Imaging (CT, MRI) helps assess extent and metastasis 1.

    • Management

  • First-line treatment: Pembrolizumab monotherapy is recommended due to high response rates in inoperable metastatic cases 1.
  • Specific drug: Pembrolizumab (dose not specified in abstract) 1.
  • Avoid combinations: Nivolumab-relatlimab combinations are not preferred over anti-PD-1 monotherapy 1.

    • Special Populations

  • No specific recommendations provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.

    • Key Recommendations

  • Consider pembrolizumab monotherapy as the first-line treatment for inoperable metastatic desmoplastic melanoma due to high efficacy 1 (Evidence: Strong).
  • Anti-PD-1 monotherapy should be prioritized over combination therapies like nivolumab-relatlimab 1 (Evidence: Moderate).
  • Further studies are needed to establish treatment protocols for special populations including elderly patients and those with comorbidities 1 (Evidence: Expert opinion).

    • References

    1 . Single-Agent PD-1 Blockade Is "Treatment of Choice" for Desmoplastic Melanoma. Cancer discovery 2023. link

    Original source

    1. [1]
      Single-Agent PD-1 Blockade Is "Treatment of Choice" for Desmoplastic Melanoma. Cancer discovery (2023)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG